Call Options

18 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$0.41 - $0.64 $185,115 - $288,960
-451,500 Reduced 94.95%
24,000 $9,000
Q2 2022

Aug 15, 2022

SELL
$0.42 - $0.65 $420 - $650
-1,000 Reduced 0.21%
475,500 $290,000
Q1 2022

May 16, 2022

BUY
$0.54 - $2.74 $81,702 - $414,562
151,300 Added 46.53%
476,500 $286,000
Q4 2021

Feb 14, 2022

BUY
$2.33 - $3.37 $669,409 - $968,201
287,300 Added 758.05%
325,200 $868,000
Q2 2021

Aug 11, 2021

SELL
$2.6 - $3.65 $620,100 - $870,525
-238,500 Reduced 86.29%
37,900 $108,000
Q1 2021

May 17, 2021

BUY
$2.73 - $4.5 $409,500 - $675,000
150,000 Added 118.67%
276,400 $948,000
Q4 2020

Feb 16, 2021

SELL
$2.6 - $3.32 $114,140 - $145,748
-43,900 Reduced 25.78%
126,400 $334,000
Q3 2020

Nov 16, 2020

BUY
$2.46 - $4.27 $170,970 - $296,764
69,500 Added 68.95%
170,300 $531,000
Q2 2020

Aug 14, 2020

BUY
$1.45 - $4.3 $78,155 - $231,770
53,900 Added 114.93%
100,800 $416,000
Q3 2019

Nov 14, 2019

SELL
$1.48 - $2.52 $271,432 - $462,168
-183,400 Reduced 79.64%
46,900 $79,000
Q2 2019

Aug 14, 2019

BUY
$2.45 - $3.32 $286,405 - $388,108
116,900 Added 103.09%
230,300 $576,000
Q1 2019

May 15, 2019

BUY
$2.52 - $3.24 $65,016 - $83,592
25,800 Added 29.45%
113,400 $348,000
Q4 2018

Feb 14, 2019

SELL
$1.92 - $4.1 $988,032 - $2.11 Million
-514,600 Reduced 85.45%
87,600 $231,000
Q3 2018

Nov 14, 2018

SELL
$3.39 - $4.61 $142,041 - $193,159
-41,900 Reduced 6.51%
602,200 $2.6 Million
Q2 2018

Aug 14, 2018

BUY
$1.89 - $4.95 $934,416 - $2.45 Million
494,400 Added 330.26%
644,100 $2.54 Million
Q1 2018

May 15, 2018

BUY
$2.06 - $2.38 $235,870 - $272,510
114,500 Added 325.28%
149,700 $310,000
Q4 2017

Feb 14, 2018

SELL
$1.91 - $2.83 $419,245 - $621,185
-219,500 Reduced 86.18%
35,200 $74,000
Q3 2017

Nov 14, 2017

BUY
$2.44 - $2.91 $621,468 - $741,177
254,700
254,700 $683,000

Others Institutions Holding MEIP

# of Institutions
1
Shares Held
2K
Call Options Held
0
Put Options Held
0

About MEI Pharma, Inc.


  • Ticker MEIP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 133,261,000
  • Market Cap $373M
  • Description
  • MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...
More about MEIP
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.